Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts

Published:2018-11-26 Issue:2 Volume:94 Page:257-265
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Short Nicholas J.¹^ORCID,Jabbour Elias¹^ORCID,Albitar Maher²,de Lima Marcos³,Gore Lia⁴,Jorgensen Jeffrey¹,Logan Aaron C.⁵^ORCID,Park Jae⁶,Ravandi Farhad¹,Shah Bijal⁷,Radich Jerald⁸,Kantarjian Hagop¹^ORCID

Affiliation:

1. The University of Texas MD Anderson Cancer Center; Houston Texas

2. NeoGenomics Laboratories, Inc.; Aliso Viejo California

3. University Hospitals; Cleveland Ohio

4. Children's Hospital Colorado and University of Colorado Cancer Center; Aurora Colorado

5. University of California San Francisco; San Francisco California

6. Memorial Sloan Kettering Cancer Center; New York New York

7. Moffitt Cancer Center; Tampa Florida

8. Fred Hutchinson Cancer Research Center; Seattle Western Australia

Funder

PLATO (Physicians Learning and Teaching in Oncology) Foundation

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25338/fullpdf

Reference76 articles.

1. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial;Sive;Br J Haematol,2012

2. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia;Fielding;Blood,2014

3. Has MRD monitoring superseded other prognostic factors in adult ALL?;Bruggemann;Blood,2012

4. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia;Bruggemann;Blood,2006

5. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies;Gokbuget;Blood,2012

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

2. How I use next-generation sequencing–MRD to plan approach and prevent relapse after HCT for children and adults with ALL;Blood;2024-07-18

3. Risk factors for positive post-transplantation measurable residual disease in patients with acute lymphoblastic leukemia;Chinese Medical Journal;2024-07-09

4. Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions;Leukemia;2024-06-20

5. MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications;Current Hematologic Malignancy Reports;2024-06-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3